Opinion | Who accesses effective weight-loss drugs

The article discusses the recent decline in American obesity rates, which peaked in 2022 and has been decreasing since, largely due to the increased use of GLP-1 medications like Ozempic and Zepbound. These drugs not only aid weight loss but also help prevent serious health conditions such as heart attacks and strokes, making them a valuable treatment option. However, access remains limited due to high costs, insurance coverage gaps, and patient dropout, highlighting the need for broader coverage and continued efforts to address the food environment contributing to obesity.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل